All filters
Slidesets
Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis. | I. Gardner
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. Hatley
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS | K. Dooley
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A translational modelling and simulations approach to exploit pre-clinical tuberculosis data | S. Wicha
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling | R. Rajoli
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSB
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Rifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection | H. Blumberg
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
High drug tolerance of Mycobacterium tuberculosis in caseum | J. Sarathy
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Exploration of Non-Replicating Mycobacterium Tuberculosis In Vitro System Through Mathematical Modelling | A. Schipani
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A model-based analysis to describe bedaquiline’s exposure-response relationship and predict the impact of drug-drug interactions | E. Svensson
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Population Pharmacokinetics of AZD5847 in Adults with Pulmonary Tuberculosis | C. Peloquin
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin | R. Svensson
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Methods of MR fat quantification and their pros and cons | Michael Middleton, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Noninvasive imaging methods for assessment of liver damage in NASH | Bachir Taouli, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
NASH and Fibroscan | Raj Vuppalanchi, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_04 - Blood-based Protein Biomarkers of NASH | Dr. S. Williams
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_05 - Validation of multiparametric MRI in the assessment and staging of non-alcoholic fatty liver disease | Dr. P. Eddowes
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
LiverMultiScan – quantitative MR imaging for NASH | Rajarshi Banerjee
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_06 - Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial | Dr. A. Sanyal
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Need for Biomarker Development in Non-Alcoholic Fatty Liver Disease | Eric Lefebvre, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Principles of Biomarker Development | Margery Connelly, PhD, MBA
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Quantitative measures of liver health | Grey Everson, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Defining the gold standard in Biomarker Validation in NAFLD | Arun Sanyal, MD, MBBS
Presented at:
International Workshop on NASH Biomarkers 2016